Table 1.
Clinical Characteristics and Kidney Biopsy Findings of Present Cases
| Case | Age, y/Sex | Diagnosis | HCQ Doses per BW, mg/kg | Duration of HCQ Treatment at Biopsy, mo | Cumulative HCQ Dose at Biopsy, g | Urinary Protein at Biopsy, g/g Cr | Scr at Biopsy, mg/dL | Diagnosis of Kidney Biopsy | Treatment | Observation Period After Biopsy, mo | Urinary Protein After Biopsy, g/g Cr | Scr After Biopsy, mg/dL | Maximum No. of Zebra Bodies per Cell; Cell Type; No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 34/F | SLE | 5.9 | 8 | 63 | 0.35 | 0.54 | III(A/C) | PSL, MMF, HCQ | 8 | 0.17 | 0.78 | Mes; 2 |
| 2 | 51/F | SLE | 5.5 | 28 | 243 | 2.9 | 0.77 | IV-S(A/C) | PSL, MMF, HCQ | 8 | 0.25 | 0.74 | Pod; 3, Endo; 1 |
| 3 | 20/F | SLE, SjS | 4.3 | 4 | 27 | 1.2 | 0.49 | IV-S(A/C) | PSL, MMF, HCQ | 5 | 0 | 0.41 | Pod; 6, Mes; 1 |
| 4 | 34/F | SLE | 7.2 | 48 | 576 | 9.1 | 0.52 | IV-G(A/C)+V | PSL, MMF, Tac, HCQ | 13 | 0.49 | 0.69 | Pod; 5, PEC; 1, Endo 1 |
| 5 | 42/F | SLE, SjS, APS | 5.0 | 0.3 | 3 | 0.45 | 0.71 | III(A/C) | PSL, MMF, HCQ | 11 | 0 | 0.73 | Mes; 2, Pod; 1 |
Abbreviations: APS, antiphospholipid syndrome; BW, body weight; Endo, endothelial cell; F, female; HCQ, hydroxychloroquine; Mes, mesangial cell; MMF, mycophenolate mofetil’ PEC, parietal epithelial cell; Pod, podocyte; PSL, prednisolone; SjS, Sjögren syndrome; SLE, systemic lupus erythematosus; Tac, tacrolimus.